Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FOUAD J MOAWAD

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1447221007
CMS profile
945095
Location
LA JOLLA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$192,277.83

184 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 184 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FOUAD J MOAWAD

NPI 1447221007 · CMS profile ID 945095

Allopathic & Osteopathic Physicians / Internal Medicine

LA JOLLA, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 184 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447221007?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FOUAD J MOAWAD, NPI 1447221007, CMS profile ID 945095. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 184 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447221007?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). FOUAD J MOAWAD, NPI 1447221007, CMS profile ID 945095. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 184 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447221007?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
FOUAD J MOAWAD, NPI 1447221007, CMS profile ID 945095, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 184 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1447221007?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

184 matching records · $192,277.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 184 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 184.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Phathom Pharmaceuticals, Inc. $18.5605/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151097641 CMS
GENZYME CORPORATION $122.8205/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139665022 CMS
GENZYME CORPORATION $10,725.0005/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139665024 CMS
GENZYME CORPORATION $282.1205/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139665026 CMS
GENZYME CORPORATION $516.2005/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139665028 CMS
GENZYME CORPORATION $1,042.7005/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139665030 CMS
GENZYME CORPORATION $21.8505/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139665032 CMS
GENZYME CORPORATION $68.2305/21/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139665034 CMS
Regeneron Healthcare Solutions, Inc. $53.1005/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114116878 CMS
GENZYME CORPORATION $104.6505/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139665018 CMS
GENZYME CORPORATION $3,861.0005/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139665036 CMS
GENZYME CORPORATION $10,725.0005/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139665020 CMS
GENZYME CORPORATION $289.7405/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139665074 CMS
GENZYME CORPORATION $155.2405/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139665076 CMS
GENZYME CORPORATION $825.4005/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139665078 CMS
GENZYME CORPORATION $433.4105/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139665080 CMS
Regeneron Healthcare Solutions, Inc. $25.4905/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114116876 CMS
Merck Sharp & Dohme LLC $18.3505/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141792358 CMS
Takeda Pharmaceuticals U.S.A., Inc. $22.9405/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137636944 CMS
Intercept Pharmaceuticals, Inc. $14.7104/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113633716 CMS
Regeneron Healthcare Solutions, Inc. $91.2104/23/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114116872 CMS
Regeneron Healthcare Solutions, Inc. $5,577.0004/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114116874 CMS
Regeneron Healthcare Solutions, Inc. $602.9804/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114116868 CMS
Regeneron Healthcare Solutions, Inc. $507.2304/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114116870 CMS
Regeneron Healthcare Solutions, Inc. $88.3204/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114116866 CMS
GENZYME CORPORATION $115.7404/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139665038 CMS
GENZYME CORPORATION $752.0904/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139665126 CMS
GENZYME CORPORATION $10,725.0004/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139665040 CMS
GENZYME CORPORATION $272.5104/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139665042 CMS
GENZYME CORPORATION $917.3804/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139665044 CMS
GENZYME CORPORATION $34.3304/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139665046 CMS
GENZYME CORPORATION $34.9104/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139664998 CMS
Merck Sharp & Dohme LLC $18.3504/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141899772 CMS
Takeda Pharmaceuticals U.S.A., Inc. $21.1604/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137636942 CMS
Phathom Pharmaceuticals, Inc. $23.2804/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151097639 CMS
Regeneron Pharmaceuticals, Inc. $64.7604/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114402789 CMS
Regeneron Healthcare Solutions, Inc. $7,293.0004/02/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114116864 CMS
Regeneron Healthcare Solutions, Inc. $65.4704/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114116854 CMS
Regeneron Healthcare Solutions, Inc. $91.3804/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114116856 CMS
Regeneron Healthcare Solutions, Inc. $39.0604/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114116858 CMS
Regeneron Healthcare Solutions, Inc. $391.4004/01/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114116860 CMS
Regeneron Healthcare Solutions, Inc. $118.2404/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114116862 CMS
Celltrion USA Inc. $18.5103/26/2024 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1075855365 CMS
Regeneron Healthcare Solutions, Inc. $37.0003/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114116850 CMS
Regeneron Healthcare Solutions, Inc. $34.8403/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114116852 CMS
ABBVIE INC. $22.6703/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105048538 CMS
ABBVIE INC. $97.6303/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105048536 CMS
Regeneron Healthcare Solutions, Inc. $27.4003/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114116848 CMS
Phathom Pharmaceuticals, Inc. $125.0003/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151097637 CMS
Regeneron Healthcare Solutions, Inc. $10,725.0003/07/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114116846 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,012.33 33
PY2020 $3,549.26 10
PY2021 $13,961.61 41
PY2022 $89,166.84 100
PY2023 $219,727.52 202
PY2024 $192,277.83 184
PY2025 $205,553.24 189

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $37,655.55 26
PY2024 Principal investigator $39,968.74 10
PY2022 Principal investigator $20,216.48 11
PY2021 Principal investigator $30,992.69 11
PY2020 Principal investigator $21,307.50 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $973.21 10/23/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184137007
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,100.00 10/09/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184137005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,950.00 09/12/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136997
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 09/12/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $745.77 08/14/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136993
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,687.38 08/14/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $745.77 06/24/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136983
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $745.77 06/24/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136985
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,192.83 06/24/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136987
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 06/12/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 06/12/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,200.00 06/12/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136979
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,000.00 06/12/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136981
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,684.69 04/08/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,988.07 04/01/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136963
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $745.77 03/11/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $745.77 02/11/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $908.40 01/29/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $757.35 01/17/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136955
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,303.27 01/07/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $353.60 01/07/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136939
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $132.60 01/07/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136941
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $165.10 01/07/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $70.20 01/07/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136945
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $193.70 01/07/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136947
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $66.30 01/07/2025 Covered Recipient Teaching Hospital
SCRIPPS MERCY HOSPITAL
A Phase 2, 2-Part, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis No dispute reported 06/30/2026 1184136949